Vimarsana
Biggest News Aggregation in the World

Page 10 - Genetics Research News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Genetics Research. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Genetics Research Today - Breaking & Trending Today

ViGeneron announces research collaboration with Daiichi Sankyo to evaluate vgAAV for novel ... - Vimarsana News

ViGeneron announces research collaboration with Daiichi Sankyo to evaluate vgAAV for novel ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. ViGeneron announces research collaboration with Daiichi Sankyo to evaluate vgAAV for novel ... ViGeneron GmbHJanuary 18, 2021 GMT MUNICH, Germany, Jan. 18, 2021 (GLOBE NEWSWIRE) -- ViGeneron GmbH, a gene therapy company, today announced a research collaboration to utilize its novel engineered adeno-associated virus (vgAAV) vectors with Daiichi Sankyo Company, Limited (“Daiichi Sankyo”), for delivering a novel therapeutic protein to address an undisclosed target in a highly prevalent ophthalmic d...

Source: apnews.com
Pfizer Doses First Participant in Phase 3 Study for Duchenne Muscular Dystrophy Investigational Gene Therapy - Vimarsana News

Pfizer Doses First Participant in Phase 3 Study for Duchenne Muscular Dystrophy Investigational Gene Therapy

Press release content from Business Wire. The AP news staff was not involved in its creation. Pfizer Doses First Participant in Phase 3 Study for Duchenne Muscular Dystrophy Investigational Gene Therapy January 7, 2021 GMT NEW YORK--(BUSINESS WIRE)--Jan 7, 2021-- Pfizer Inc. (NYSE: PFE) today announced that the first participant has been dosed in the Phase 3 CIFFREO study, which will evaluate the efficacy and safety of investigational gene therapy candidate PF-06939926 in boys with Duchenne muscular dystrophy (DMD). The CIFFREO trial is expected to enroll 99 ambulatory male patients, ages 4 t...

Source: apnews.com
Almirall and Tyris Therapeutics enter into strategic partnership to develop next generation gene therapies - Vimarsana News

Almirall and Tyris Therapeutics enter into strategic partnership to develop next generation gene therapies

Press release content from PR Newswire. The AP news staff was not involved in its creation. Almirall and Tyris Therapeutics enter into strategic partnership to develop next generation gene therapies January 7, 2021 GMT Almirall_Logo BARCELONA, Spain, Jan. 7, 2021 /PRNewswire/ -- Almirall, S.A. (BME: ALM), a global biopharmaceutical company based in Barcelona, and Tyris Therapeutics, a next-generation gene therapy company founded by Columbus Venture Partners, have announced a strategic partnership today to tackle orphan dermatological conditions using non-viral gene therapies. By combining Tyr...

Source: apnews.com
Autism theory 25 years in the making - Vimarsana News

Autism theory 25 years in the making

 E-Mail IMAGE: T.A. Meridian McDonald, PhD, a research instructor in Neurology at Vanderbilt University Medical Center view more  Credit: Vanderbilt University Medical Center A unifying explanation of the cause of autism and the reason for its rising prevalence has eluded scientists for decades, but a theoretical model published in the journal Medical Hypotheses describes the cause as a combination of socially valued traits, common in autism, and any number of co-occurring disabilities. T.A. Meridian McDonald, PhD, a research instructor in Neurology at Vanderbilt University Medica...

"Historic" release of six improved wheat varieties in Nepal – CIMMYT - Vimarsana News

"Historic" release of six improved wheat varieties in Nepal – CIMMYT

Wheat fields at Toluca station, Mexico. (Photo: Fernando Delgado/CIMMYT) On December 11, 2020, the Nepal Agricultural Research Council (NARC) announced the release of six new wheat varieties for multiplication and distribution to the country’s wheat farmers, offering increased production for Nepal’s nearly one million wheat farmers and boosted nutrition for its 28 million wheat consumers. The varieties, which are derived from materials developed by the International Maize and Wheat Improvement Center (CIMMYT), include five bred for elevated levels of the crucial micronutrient zinc, and Bo...

Source: cimmyt.org